<DOC>
	<DOCNO>NCT00165399</DOCNO>
	<brief_summary>The purpose study see combination chemotherapy drug drug suppress testosterone ( hormone therapy ) effective control early prostate cancer . This study attempt : - stop slow growth disease - gain information prostate cancer - evaluate effectiveness side effect study drug</brief_summary>
	<brief_title>Docetaxel , Estramustine Short Term Androgen Withdrawal Patients With Rising PSA After Local Treatment</brief_title>
	<detailed_description>- Patients receive two medication ; docetaxel estramustine . Estramustine take orally three time daily 5 day start day one . Docetaxel give intravenously day 2 . These two drug repeat every 3 week total 4 cycle ( 12 week ) . - Patients also take dexamethasone three day begin cycle help decrease risk side effect . - Patients also take coumadin every day three month chemotherapy reduce risk blood clot . - After 12 week chemotherapy phase complete patient start hormone therapy part treatment . Three week last chemotherapy treatment , patient start Casodex orally daily . - After take Casodex 1 week , patient start Zoladex ( injection abdomen ) every 3 month total 5 injection . - During study treatment various blood test perform watch disease . Study treatment stop total 18 month ( 3 month chemotherapy 15 month hormone therapy ) . A physical exam blood test perform every 3 month 2 year , every 4 month third year , every 6 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologically document adenocarcinoma prostate Previous treatment either radical prostatectomy radiation therapy Post prostatectomy : PSA rise least two successive occasion least two week apart Post radiation therapy alone : PSA rise document two successive occasion least two week apart also double nadir post treatment value ECOG performance status 01 ANC &gt; 1,500/mm3 Platelet count &gt; 100,000/mm3 SGOT and/or SGPT may 2.5 x ULN Documented local recurrence prostate cancer document metastatic disease History malignancy within last 5 year , curatively treat basal cell carcinoma skin Medical condition require use concommitant corticosteroid Active infection Significant cardiac disease , angina pectoris myocardial infarction within six month Prior chemotherapy include estramustine , suramin Active thrombophlebitis history thromboembolic event six month precede study treatment Clinically significant neuropathy Elevated bilirubin ULN</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>PSA level</keyword>
	<keyword>docetaxel</keyword>
	<keyword>estramustine</keyword>
	<keyword>hormone therapy</keyword>
	<keyword>androgen withdrawal</keyword>
</DOC>